Surmodics partners with Abbott to develop drug-coated balloon

Abbott and Surmodics announced an agreement for Abbott to have exclusive worldwide commercialization rights for Surmodics' SurVeil drug-coated balloon to treat the superficial femoral artery. Abbott also received options for below-the-knee and AV fistula drug-coated balloon products.

“We are excited to enter this partnership with Abbott given its deep expertise in vascular care products and its worldwide strength in the market.”vascularnews.com

• 1 source
• vascularnews.comSurmodics partners with Abbott to develop their next-generation DCB - Vascular NewsMar 1, 2018

Summarized from public sources; check the original articles before acting on it.